Cartesian Therapeutics, Inc. (RNAC)
Nasdaq · Healthcare · Biotechnology
$7.14−2.99%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $216M
- 52-week range
- $5.60 – $11.00
- 52-week change
- −24.44%
- EPS (trailing)
- −$5.78
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $2.8M (−92.81%)
- Net income
- −$130M
- Operating margin
- −5127.3%
- Diluted EPS
- −$5.02
- Free cash flow
- −$79.4M
From the company’s annual report on SEC EDGAR.
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Headquarters: Frederick, United States · 75 employees · cartesiantherapeutics.com